



CardioDx to Present at the Jefferies 2013 Global Healthcare Conference

PALO ALTO, Calif. – May 30, 2013 – CardioDx, Inc., a pioneer in the field of [cardiovascular genomic diagnostics](#), today announced that the company will present at the Jefferies 2013 Global Healthcare Conference, taking place June 3-6, 2013 in New York, NY. David Levison, the company's President and Chief Executive Officer, will provide an overview of CardioDx and [Corus[®] CAD](#), the only clinically validated [gene expression test](#) for [obstructive coronary artery disease](#) (CAD) on Wednesday, June 5, 2013 at 10:30 AM ET.

CardioDx recently announced the publication of the IMPACT-CARD trial (Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern) in *Critical Pathways in Cardiology*, a journal of the Society of Cardiovascular Patient Care¹. The prospective U.S. study showed that integrating Corus CAD in the cardiology practice significantly influenced clinicians' diagnostic strategy in assessing patients presenting with typical or atypical symptoms suggestive of obstructive CAD. The study found that cardiologists changed their diagnostic testing strategy in 58 percent of patients ($p < 0.001$), and there was an overall reduction in testing after obtaining the Corus CAD test result. A separate prospective, multi-center study, COMPASS², found that the Corus CAD gene expression test outperformed traditional stress testing with myocardial perfusion imaging (MPI). COMPASS revealed Corus CAD to have a significantly higher sensitivity (89 percent vs. 27 percent, $p < 0.001$) and significantly higher negative predictive value (96 percent vs. 88 percent, $p < 0.001$) than MPI for assessing the presence of obstructive CAD.

With a simple blood draw, Corus CAD can safely, accurately and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient's symptoms are due to obstructive CAD, enabling many patients to avoid unnecessary noninvasive and invasive cardiac procedures and exposure to imaging-related radiation risks or imaging agent intolerance. Corus CAD is the only sex-specific test for obstructive CAD, accounting for critical biological differences between men and women. Corus CAD has been used commercially by clinicians in more than 38,000 patients and is a covered benefit for more than 40 million Medicare enrollees in the U.S. CardioDx processes all Corus CAD test specimens at its CLIA-certified and CAP-accredited clinical laboratory in Palo Alto, CA.

Corus CAD has been recognized by *The Wall Street Journal's* Technology Innovation Awards, honored as a Gold Edison Award recipient and named one of *TIME's* Top Ten Medical Breakthroughs. CardioDx was recently honored as one of *FierceMedicalDevices'* "Fierce 15" most promising privately-held medical device and diagnostic companies.

About CardioDx

CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit www.cardiodx.com.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements regarding the business strategy of CardioDx, the safety and efficacy, adoption rate and size of the market for Corus CAD, and beliefs regarding the need for and value of gene expression diagnostics. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These statements reflect the views of CardioDx as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

###

For investor relations inquiries, please contact Lynn Pieper of Westwicke Partners, +1-415-202-5678, lynn.pieper@westwicke.com.

For media inquiries, please contact Wenli Chiu of Lazar Partners, +1-646-871-8492, wchiu@lazarpartners.com.

¹ McPherson JA, Davis K, Yau M, et al. The Clinical Utility of Gene Expression Testing on the Diagnostic Evaluation of Patients Presenting to the Cardiologist with Symptoms of Suspected Obstructive Coronary Artery Disease: Results from the IMPACT (Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern) Trial. *Crit Pathw Cardiol*. 2013;12(2):37-42.

² Thomas GS, Voros S, McPherson JA, et al. A Blood Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging: The COMPASS Study. *Circ Cardiovasc Genet*. 2013;6(2):154-162.